Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 8172 results

  1. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 9 February 2026.

    Technology appraisal guidance
    In consultation

  2. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.

    Technology appraisal guidance
    In consultation

  3. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 12 February 2026.

    Technology appraisal guidance
    In consultation

  4. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]

    In development Reference number: GID-TA11765 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]

    In development Reference number: GID-TA11859 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Guidance on the use of electroconvulsive therapy: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 16 February 2026.

    Technology appraisal guidance
    In consultation

  7. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400

    Awaiting development Reference number: GID-TA11509 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]

    Awaiting development Reference number: GID-TA11840 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Kidney Cancer Quality Standard

    In development Reference number: GID-QS10186 Expected publication date:  19 March 2026

    Quality standard
    In development

  11. Statement of intent on NICE's approach to ongoing evaluations ahead of proposed changes to NICE's standard cost-effectiveness thresholds: nice general consultation

    We are listening to your views on this NICE general. Comments close 30 January 2026.

    NICE guideline
    In consultation

  12. Etavopivat for treating sickle cell disease in people 12 years and over [TSID12320]

    Awaiting development Reference number: GID-TA11912 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [TSID12315]

    Awaiting development Reference number: GID-TA11913 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

    Quality standard
    In development

  15. Luspatercept for Anaemia due to myelodysplastic syndromes [TSID12310]

    Awaiting development Reference number: GID-TA11914 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development